| 3/24/2025 | CVLM | Insulet to repurchase $419 million of 0.375% convertibles
|
| 3/19/2025 | BKCVDDEMIGPV | Market Commentary: Bausch Health joins junk calendar, debt stack mixed on redemptions; Insulet shoots higher
|
| 3/18/2025 | BKCVDDEMIGPV | Market Commentary: Insulet prices; Mohegan joins junk calendar; Outbrain crumbles; Hertz under pressure
|
| 3/18/2025 | CV | Market Commentary: Sarepta convertible notes in focus, gain on hedge as stock drops; Lucid improves
|
| 3/18/2025 | BKCVHY | Moody's rates Insulet loan Ba2, notes B2
|
| 3/18/2025 | CVLM | Insulet to redeem 0.375% convertibles due 2026 with note proceeds
|
| 3/18/2025 | BKCV | S&P hikes Insulet, rates notes B+
|
| 3/18/2025 | CV | Market Commentary: Morning Commentary: Sarepta convertible notes in focus, improve on hedge as stock drops
|
| 11/9/2023 | BKCV | S&P lifts Insulet
|
| 10/13/2023 | CV | Market Commentary: DexCom, Insulet convertible notes active, level off after sell-off; PagerDuty below par
|
| 10/13/2023 | CV | Market Commentary: Morning Commentary: DexCom, Insulet convertible notes active, level off after sell-off
|
| 10/12/2023 | CV | Market Commentary: Rivian convertible notes weaken; Insulet down outright, up on hedge amid Ozempic hit
|
| 9/25/2023 | BKCV | Moody’s raises Insulet loans
|
| 8/30/2023 | CV | Market Commentary: Insulet convertible notes in focus; DexCom gains; Wayfair active in secondary market
|
| 8/30/2023 | CV | Market Commentary: Morning Commentary: Convertibles secondary trading quiet but firm; Insulet notes jump
|
| 8/22/2023 | CV | Market Commentary: PureCycle green convertible notes jump on debut; Insulet active; Akamai improves
|
| 8/22/2023 | CV | Market Commentary: Morning Commentary: PureCycle prices green convertible notes; Insulet active early
|
| 3/13/2023 | CV | Market Commentary: Investment-grade convertible notes in focus; Alliant tops par; Insulet paper gains
|
| 12/13/2022 | CV | Market Commentary: Marriott Vacations convertibles gain; DISH notes higher in heavy volume; Insulet lifted
|
| 11/7/2022 | CV | Market Commentary: Convertibles secondary quiet; Insulet adds; Pinduoduo active; MongoDB drops to par
|
| 11/4/2022 | CV | Market Commentary: Secondary quiet amid equity volatility; Insulet, Cryoport convertibles in focus post-earnings
|
| 11/4/2022 | CV | Market Commentary: Morning Commentary: Insulet convertibles in focus on earnings beat
|
| 5/31/2022 | CV | Market Commentary: ConMed convertibles on tap; Asian names rally; Pinduoduo jumps; Insulet up on swap
|
| 4/1/2022 | BKCV | S&P revises Insulet view to positive
|
| 1/28/2022 | CV | Market Commentary: Affirm convertibles gain in active trading; Insulet pops on FDA nod; Lucid down again
|
| 1/28/2022 | CV | Market Commentary: Morning Commentary: Volatility in equities continues; Insulet convertible notes pop
|
| 10/4/2021 | CVLM | Insulet to redeem all 1.375% convertibles due 2024
|
| 4/19/2021 | BKCV | Moody's assigns Insulet, loans Ba3
|
| 4/19/2021 | BKCV | S&P rates Insulet B, facility B+
|
| 2/26/2020 | CV | Market Commentary: NuVasive convertible offering eyed; Bandwidth expands on debt; Exact Sciences volatile
|
| 2/14/2020 | CV | Market Commentary: SSR Mining convertible notes in focus on call news; Wayfair active; Dexcom, Insulet gain
|
| 9/26/2019 | CV | Market Commentary: Morning Commentary: Broadcom mandatory remains active in trade; Insulet trades at 102
|
| 9/23/2019 | CV | Market Commentary: Pinduoduo pricing notes; Fortive trades in size; SailPoint, Etsy trade; Avadel stock up
|
| 9/23/2019 | CV | Market Commentary: Morning Commentary: Convertible notes mostly quiet; SailPoint trades just under par
|
| 9/16/2019 | CVLM | Insulet to redeem all 1.25% convertible notes due 2021 on Oct. 28
|
| 9/10/2019 | CV | Market Commentary: Chesapeake convertibles move up on debt-for-equity news; Okta contracts; Harmonic on tap
|
| 9/10/2019 | CV | Market Commentary: Morning Commentary: Chesapeake Energy moves on debt-for-equity news; new paper slips
|
| 9/9/2019 | CV | Market Commentary: Convertibles trade in line on swap; profit taking strikes a few names; Insulet drops with shares
|
| 9/9/2019 | CV | Insulet greenshoe exercise increases convertibles to $800 million
|
| 9/6/2019 | CV | Market Commentary: Invitae convertible adds outright; Talend deal prices in busy holiday-shortened week
|
| 9/6/2019 | CV | Market Commentary: Morning Commentary: Convertibles primary active for week; Talend, Invitae tap market
|
| 9/4/2019 | CV | Market Commentary: Insulet edges up after upsizing, pricing at rich end of talk; primary calendar builds
|
| 9/4/2019 | CV | Market Commentary: Morning Commentary: New Insulet edges up after upsizing, pricing at rich end of talk
|
| 9/4/2019 | CV | New Issue: Insulet prices upsized $700 million seven-year convertibles to yield 0.375%, up 35%
|
| 9/3/2019 | CV | Market Commentary: Convertibles primary active: Insulet, Zillow, Okta, Aerie Pharma, Encore launch deals
|
| 9/3/2019 | CV | Market Commentary: Morning Commentary: Insulet launches $660 million seven-year convertibles; valuation eyed
|
| 9/3/2019 | CV | Insulet to price $660 million seven-year convertible notes to yield 0.375%-0.875%, up 30%-35%
|
| 1/9/2018 | CV | Market Commentary: Wheeler to price add on to 8.75% preferreds; Insulet in demand; GoPro holders hold on
|
| 1/9/2018 | CV | Market Commentary: Morning Commentary: Wheeler to price $25 million add on to 8.75% preferreds, Insulet in demand
|
| 11/16/2017 | CV | Market Commentary: Everbridge expands on debut, RH dominates trading, Quotient eclipses Rambus, Insulet active
|
| 11/14/2017 | CV | Market Commentary: Morning Commentary: Rambus, Quotient deals in pipeline, Insulet drops below par, Tesla gains
|
| 11/13/2017 | CV | Insulet greenshoe ups 1.375% convertibles due 2024 to $402.5 million
|
| 11/9/2017 | CV | Market Commentary: New deals from Sarepta, Insulet trade high on reputation, new issuance drought
|
| 11/9/2017 | CV | Market Commentary: Morning Commentary: Sarepta’s upsized 1.5% notes ‘well received’ in market debut
|
| 11/8/2017 | CV | Market Commentary: Insulet, Arbor Realty deals hit market; Sarepta upsizes deal; GNC and Aegean Marine plummet
|
| 11/8/2017 | CV | Market Commentary: Morning Commentary: New Insulet 1.375% convertibles trade above par, high demand
|
| 11/8/2017 | CV | New Issue: Insulet prices upsized $350 million seven-year convertibles to yield 1.375%, up 30%
|
| 11/8/2017 | CVLM | Insulet to use $99 million in buyback of $63.4 million 2% convertibles
|
| 11/7/2017 | CV | Market Commentary: Apollo add-on active in trading, Insulet deal upsized, Sarepta Therapeutics plans new deal
|
| 11/7/2017 | CV | Market Commentary: Morning Commentary: Apollo Commercial details add-on pricing; secondary trading active
|
| 11/6/2017 | CV | Market Commentary: Apollo, Insulet to price new deals, NXP Semiconductors makes gains
|
| 11/6/2017 | CV | Insulet to price $300 million seven-year convertibles to yield 1.375%-1.875%, up 25%-30%
|
| 9/15/2016 | CV | Market Commentary: Convertibles quiet after softening earlier in the week; energy names in focus, weaker
|
| 9/13/2016 | CV | Insulet greenshoe exercise increases convertibles to $345 million
|
| 9/8/2016 | CV | Market Commentary: New Insulet in line to better on debut; old Insulet slips; Ctrip.com, Inphi remain firm
|
| 9/8/2016 | CV | Market Commentary: Morning Commentary: New Insulet convertible trading up a point on swap
|
| 9/7/2016 | CVLM | Insulet plans to repurchase $134 million of 2% convertibles due 2019
|
| 9/7/2016 | CV | New Issue: Insulet prices upsized $300 million 1.25% five-year convertibles, up 32.5%
|
| 9/7/2016 | CV | Market Commentary: Ctrip.com trades a little over par despite lower shares; Inphi bond adds; Retrophin surges
|
| 9/6/2016 | CV | Market Commentary: Four U.S. deals launch post-holiday; three international deals surface; Navistar pops
|
| 9/6/2016 | CV | Insulet to price $250 million five-year convertible notes to yield 1.25%-1.75%, up 27.5%-32.5%
|
| 8/13/2015 | CV | Market Commentary: SunEdison improves; Iconix up; Whiting Petroleum flat; Hercules Offshore files Chapter 11
|
| 5/1/2015 | CV | Market Commentary: New CalAmp up in active trade; LinkedIn expands; Blucora, Insulet, Web.com better on swap
|
| 5/1/2015 | CV | Market Commentary: Morning Commentary: New, upsized CalAmp adds in active trade; LinkedIn notes improve
|
| 1/8/2015 | CV | Market Commentary: Medicines adds on hedge in busy trade; Resource Capital slips from discounted offer price
|
| 6/17/2014 | CVLM | Insulet holders may convert 3.75% notes till July 24; call issued
|
| 6/6/2014 | CV | Insulet greenshoe exercise increases convertibles to $201.25 million
|
| 6/4/2014 | CV | New Issue: Insulet prices $175 million of five-year convertibles to yield 2%, up 32.5%
|
| 6/4/2014 | CV | Market Commentary: Primary market percolates; new Insulet, Jakks trade higher; Illumina launches dual tranches
|
| 6/4/2014 | CV | Market Commentary: Midday Commentary: New Insulet, Jakks trade higher; SunEdison launches new convertible for $500 million
|
| 6/3/2014 | CV | Insulet plans $175 million of five-year convertibles to yield 2%-2.5%, up 27.5%-32.5%
|
| 6/3/2014 | CV | Market Commentary: Jakks shares drop ahead of pricing; Insulet, Laclede, and TPG Specialty launch new deals
|
| 5/8/2014 | CV | Market Commentary: Cobalt gains on debut; existing Cobalt slips; Molycorp slides after earnings; Insulet adds
|
| 6/28/2011 | CV | Insulet greenshoe lifts 3.75% convertibles due 2016 to $143.75 million
|
| 6/24/2011 | CV | New Issue: Insulet sells upsized $125 million five-year convertibles to yield 3.75%, up 32.5%
|
| 6/24/2011 | CV | Market Commentary: New Insulet adds on swap; purchases of older Insulet planned; NuVasive dips; Micron lower
|
| 6/23/2011 | CV | Market Commentary: New NuVasive trades actively around par, adds on hedge; Jefferies flat on hedged basis
|
| 6/22/2011 | CV | Insulet to price $110 million five-year convertible notes to yield 3.5%-4%, up 30%-35%
|
| 6/22/2011 | CV | Market Commentary: Planned NuVasive looks slightly cheap; existing NuVasive contracts; Insulet paper on tap
|
| 3/11/2011 | CVHYPF | Insulet files $150 million shelf covering preferreds, common stock
|
| 4/1/2009 | CVHY | Insulet files $150 million shelf registration
|
| 6/20/2008 | CV | Insulet greenshoe fully exercised, lifts 5.375% five-year convertibles to $85 million
|
| 6/13/2008 | CV | Market Commentary: KeyCorp edges up in debut; Lehman finds footing; Cameron lower; Energy Conversion on tap Wednesday
|
| 6/12/2008 | CV | Market Commentary: KeyCorp deal eyed ahead of pricing; Lehman active; Coors slips on rival's buyout news; Invitrogen in line
|
| 6/11/2008 | CV | Market Commentary: Lehman, WaMu lead losses; Carrizo Oil adds early; Sotheby's price talk emerges
|
| 6/11/2008 | CV | New Issue: Insulet prices upsized $75 million five-year convertibles to yield 5.375%, up 34%
|
| 6/10/2008 | CV | Insulet prices upsized $75 million five-year convertibles to yield 5.375%, up 34%
|
| 6/10/2008 | CV | Market Commentary: Freeport adds on more takeout speculation, Grey Wolf contracts on merger news; Alpha Natural pressured
|
